• Please log in or register to access this feature.

Original Article

Late motor decline after accomplished remyelination: Impact for progressive multiple sclerosis

  1. Natalia Manrique-Hoyos MSc1,
  2. Tanja Jürgens MSc2,3,4,
  3. Mads Grønborg PhD5,6,
  4. Mario Kreutzfeldt MSc2,3,4,
  5. Mariann Schedensack2,3,
  6. Tanja Kuhlmann MD7,
  7. Christina Schrick2,3,
  8. Wolfgang Brück MD2,3,
  9. Henning Urlaub PhD6,
  10. Mikael Simons MD1,8,†,*,
  11. Doron Merkler MD2,3,4

Article first published online: 24 FEB 2012

DOI: 10.1002/ana.22681

Issue

Annals of Neurology

Annals of Neurology

Volume 71, Issue 2, pages 227–244, February 2012

Additional Information

How to Cite

Manrique-Hoyos, N., Jürgens, T., Grønborg, M., Kreutzfeldt, M., Schedensack, M., Kuhlmann, T., Schrick, C., Brück, W., Urlaub, H., Simons, M. and Merkler, D. (2012), Late motor decline after accomplished remyelination: Impact for progressive multiple sclerosis. Ann Neurol., 71: 227–244. doi: 10.1002/ana.22681

Author Information

  1. 1

    Max Planck Institute for Experimental Medicine; Max Planck Institute for Biophysical Chemistry, Göttingen, Germany

  2. 2

    Division of Clinical Pathology, Geneva University Hospital, Geneva, Switzerland

  3. 3

    Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland

  4. 4

    Department of Neuropathology, University Medical Center, Georg August University, Göttingen, Germany

  5. 5

    Department of Neurobiology, Max Planck Institute for Biophysical Chemistry, Göttingen, Germany

  6. 6

    Bioanalytical Mass Spectrometry Group, Max Planck Institute for Biophysical Chemistry, Germany

  7. 7

    Institute of Neuropathology, University Hospital Münster, Münster, Germany

  8. 8

    Department of Neurology, University Medical Center, Georg August University, Göttingen, Germany

  1. †

    M.S. and D.M. contributed equally to this work.

*Max-Planck-Institute of Experimental Medicine, Hermann-Rein Str. 3, 37075, Göttingen, Germany

  1. †

    M.S. and D.M. contributed equally to this work.

Publication History

  1. Issue published online: 24 FEB 2012
  2. Article first published online: 24 FEB 2012
  3. Accepted manuscript online: 25 NOV 2011 08:36AM EST
  4. Manuscript Accepted: 4 NOV 2011
  5. Manuscript Revised: 26 AUG 2011
  6. Manuscript Received: 14 NOV 2010

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article with Supporting Information (HTML) Get PDF (3478K)

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Adib Zendedel, Cordian Beyer, Markus Kipp, Cuprizone-Induced Demyelination as a Tool to Study Remyelination and Axonal Protection, Journal of Molecular Neuroscience, 2013,

    CrossRef

  2. 2
    Amanda J. Mierzwa, Yong-Xing Zhou, Norah Hibbits, Adam C. Vana, Regina C. Armstrong, FGF2 and FGFR1 Signaling Regulate Functional Recovery Following Cuprizone Demyelination, Neuroscience Letters, 2013,

    CrossRef

  3. 3
    T. Schmidt, H. Awad, A. Slowik, C. Beyer, M. Kipp, T. Clarner, Regional Heterogeneity of Cuprizone-Induced Demyelination: Topographical Aspects of the Midline of the Corpus Callosum, Journal of Molecular Neuroscience, 2013, 49, 1, 80

    CrossRef

  4. 4
    Michael B. Keough, V. Wee Yong, Remyelination Therapy for Multiple Sclerosis, Neurotherapeutics, 2013, 10, 1, 44

    CrossRef

View Full Article with Supporting Information (HTML) Get PDF (3478K)